Capacity Worries Fade for Biomanufacturing

The DSM investment puts biomanufacturing capacity in the spotlight. Contract biomanufacturers are adding new capacity and sponsors are marketing their excess capacity.

External Link - article-62505.pdf

Articles in this issue

almost 23 years ago

Article

July 2003

almost 23 years ago

Article

Gastrorentention: A Means to Address Regional Variability in Intestinal Drug Absorption

almost 23 years ago

Article

The Push for Generics Challenges Manufacturers

almost 23 years ago

Article

Emerging Research Opportunities in Oral Inhalation Technology

almost 23 years ago

Article

Understanding and Implementing a Risk-Based Approach to 21 CFR Part 11 Compliance

almost 23 years ago

Article

Preventing Metal Contamination

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Capacity Worries Fade for Biomanufacturing

Articles in this issue

Related Content

Optimizing Impact for Rare Diseases

Tom Sellig on CDMO Innovation and US Manufacturing Growth

Generic GLP-1s Enter Canadian Market

Pharma Fundamentals: Utilizing Artificial Intelligence in Drug Development

Facility Design for Optimized Contract Manufacturing

Trending on Pharmaceutical Technology

Zumilokibart: Inside AbbVie's $10.9B Pipeline Bet

Why the First Generic Single-Dose Flu Antiviral Approval Matters

Germany Pharma Tariff Threat: What Manufacturers Need to Know

PharmTech Weekly Roundup—June 19, 2026

Sustainability by Design: Re-Imagining Amorphous Dispersion Manufacturing